HSPG2 and chronic kidney disease: The group-wise random distribution of CKD patients taking ARBs was STV (61.2%) and PLC (65.1%); calcium channel blockers (CCBs) were STV (40.9%) and PLC (37.2%); and a combination of ARB and CCB was STV (2.3%) and PLC (2.3%).